Red Light Holland Secures Second United States Controlled Substances Import Permit for the Company's Psilocybin Through FDA-Compliant, DEA-Registered Partner Irvine Labs
Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an
Cannabis, Health, Psychedelics, Cannabis Ancillary Service Provider
2025-10-14 8:34 AM EDT | Red Light Holland Corp.
CBIH Announces Women-First Fertility Innovation Built on Nanoemulsion Delivery
Houston, Texas--(Newsfile Corp. - October 13, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) today announced the addition of a patent-pending nanoemulsion formulation to its growing portfolio, developed to support female fertility and reproductive function in women of advanced maternal age (35+). CBIH believes this innovation should expand evidence-based options for patients and partners. As age is a key determinant of reproductive outcomes—and first births
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-10-13 7:00 AM EDT | Cannabis Bioscience International Holdings
Numinus Wellness Announces Change of Auditor
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as the Company's independent auditor of its own initiative, and that MNP LLP ("MNP") has been eng
2025-10-10 5:00 PM EDT | Numinus Wellness Inc.
PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that all resolutions presented at the Company's annual general and special meeting (the "Meeting") held on Friday, October 10, 2025, including the following: the election of Stephen Van Deventer, Makarand Jawadekar, Kathlee
Biotechnology, Pharmaceuticals, Health
2025-10-10 4:00 PM EDT | PreveCeutical Medical Inc.
Akanda Corp. Addresses Impacts of Postal Strike on Receiving Materials for Its Upcoming Special Meeting
Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced that, due to the ongoing postal strike in Canada, the Company is unable to mail shareholder proxy materials (the "Meeting Materials") for its upcoming special meeting (the "Meeting") of shareholders scheduled for 10:00 a.m. (Toronto time) on Thursday, October 30, 2025, at the offices of Gowling WLG (Canada) LLP, Suite 1600, 100
Cannabis, Health, Cannabis Cultivator, Cannabis Manufacturer
2025-10-10 2:00 PM EDT | Akanda Corp
Konan Medical's objective FIELD(R) Perimeter Obtains CE Mark Under MDR
Irvine, California--(Newsfile Corp. - October 10, 2025) - Konan Medical USA, Inc. today announced its groundbreaking objectiveFIELD Analyzer (OFA®) has received CE Marking under the European Medical Device Regulation (MDR). This significant milestone enables the Company to offer advanced perimetry to healthcare providers across the European Union. Receiving CE Marking signifies that the device meets the stringent safety and performance requirements set forth by the Europ
2025-10-10 9:00 AM EDT | Konan Medical USA Inc.
TempraMed Receives Final Receipt for Prospectus and Closes Reverse Takeover Transaction of TempraMed Israel
Vancouver, British Columbia--(Newsfile Corp. - October 10, 2025) - TempraMed Technologies Ltd. (the "Company") is pleased to announce that the Company has filed and obtained a receipt on September 29, 2025, for its final long form prospectus dated September 25, 2025 (the "Prospectus"), with the British Columbia Securities Commission and is now a reporting issuer in the Province of British Columbia, effective as of September 29, 2025. The Prospectus was filed for, among other thi
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-10 7:00 AM EDT | TempraMed Technologies Ltd
Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board, previously announced on August 13, 2024. Mr. Raimondo
Technology, Biotechnology, Health
2025-10-10 6:30 AM EDT | Therma Bright Inc.
Apollo Biowellness, Inc., Merger Update
North Bergen, New Jersey--(Newsfile Corp. - October 9, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to announce that it has completed the first step in the closing process with Revive Regenerative, Inc. The Company has secured the initial tranche of capital required in the amount of $500,000 as set forth in the merger agreement. In addition, the Company has finalized with GSS Capital to raise the additional $3,000,000 needed, with the terms agreed
Household / Consumer / Cosmetics, Health
2025-10-09 2:48 PM EDT | Apollo Biowellness, Inc.
Hemostemix Files for Ethics Approval of its Study of Vascular Dementia
Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review Board (IRB) application for approval of its Phase 1 clinical trial titled "Treatment of Vascular Cognitive Impairment and Dementia with Angiogenic Cell Precursors (ACP-01)." The 102-page submission marks a critical milestone in expanding the therapeutic reach of ACP
Biotechnology, Pharmaceuticals, Health
2025-10-09 9:03 AM EDT | Hemostemix Inc.
Psyched Wellness Provides Comprehensive Investor Update
Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company specializing in the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to provide the following corporate update to its investors. Product Development & Launches Santa - Dietary Supplement Shot Following the initia
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2025-10-09 7:30 AM EDT | Psyched Wellness Ltd.
Neural Portfolio Company Hanf.com Reports Strong Fiscal 2024 Results with 65% Revenue Growth, Positive Cash Flow and Double-Digit Operating Margin; Continued Growth in 2025; First Half Revenues Up 31% Year-Over-Year
Toronto, Ontario--(Newsfile Corp. - October 8, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on therapeutic solutions for mental health conditions, together with its portfolio company CWE European Holdings Inc. ("CWE", operating as Hanf.com), one of Germany's leading hemp- and CBD-based retail platforms, is pleased to report the audited financial results of Hanf.com for the fis
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-08 9:37 AM EDT | Neural Therapeutics Inc.
Apollo Biowellness, Inc., Re-Engages GSS Capital
North Bergen, New Jersey--(Newsfile Corp. - October 8, 2025) - Apollo Biowellness, Inc. (OTCID: KOAN) (the "Company"), is pleased to announce that it has re-engaged GSS Capital, a licensed Investment Bank and a member of FINRA, for advisory services to assist in the restructuring of the Company's Balance Sheet, coordinate the conversion of all convertible and secured debt of the Company to allow the Company to comply with the conditions of the Letter of Intent with Revive Regenerative,
Household / Consumer / Cosmetics, Health
2025-10-08 9:30 AM EDT | Apollo Biowellness, Inc.
Hazelden Betty Ford Recognized by Newsweek's "America's Best Addiction Treatment Centers 2025"
California and Newberg, Oregon--(Newsfile Corp. - October 8, 2025) - Hazelden Betty Ford has again been recognized by Newsweek's America's Best Addiction Treatment Centers in 2025, and is the largest, most frequently named national nonprofit provider on the 2025 listings. The annual rankings name the top treatment centers nationwide by state, based on quality of care, accreditation, reputation, and patient experience. The Hazelden Betty For
2025-10-08 9:00 AM EDT | Hazelden Betty Ford Foundation
Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%
Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than 100% compared to the second quarter, while posting an extraordinary profit margin exceeding 20% for the quarter. This blockbuster performance cements Adia Nut
Healthcare and Hospitals, Health
2025-10-08 8:30 AM EDT | Adia Nutrition Inc.
Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025, regarding the Company's recently closed non-brokered private placement. The previous release incorrectly stated that the Units were issued at a price of $0.10 per Unit.
Biotechnology, Pharmaceuticals, Health
2025-10-07 5:48 PM EDT | Genix Pharmaceuticals Corp.
Hemostemix's Insider Lead Order of $330,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered private placement of up to $700,000. Purchasers may subscribe for Units at $0.11. Each Unit consists of one Common Share and one Warrant. Each Warrant may be exercised by the holder to acquire one Common Share at $0.15 for a period of two years from the Closing Date, subje
Biotechnology, Pharmaceuticals, Health
2025-10-07 10:05 AM EDT | Hemostemix Inc.
Hear At Last Launches Token on Solana Blockchain to Raise $10 Million for Portable Homes in Jamaica and North America
Miami, Florida--(Newsfile Corp. - October 7, 2025) - Hear At Last (OTCID: HRAL), a leader in innovative housing solutions, is proud to announce the creation of a new cryptocurrency token, HOHM, on the Solana blockchain. This initiative is aimed at raising $10 million to support the development and distribution of portable homes in Jamaica and North America. The HOHM token represents a groundbreaking step in combining blockchain technology with sustainable housing projects. By lev
Household / Consumer / Cosmetics, Health
2025-10-07 8:00 AM EDT | Hear AtLast Holdings, Inc
Edison Issues Report on Percheron Therapeutics (PER)
London, United Kingdom--(Newsfile Corp. - October 7, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER) Percheron Therapeutics has reported final results from the Phase I dose escalation study of HMBD-002, its monoclonal antibody targeting VISTA, a novel immune checkpoint protein. The data confirmed the compound's favourable safety and tolerability profile (maximum tolerated dose not reached with <10% of patients experiencing grade 3 or greater adverse events), with e
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-10-07 4:38 AM EDT | Edison Group
Cosmo Pharmaceuticals Announces Regulatory Approval of Winlevi(R) in South Korea
Dublin, Ireland--(Newsfile Corp. - October 7, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-driven healthcare and specialty pharmaceuticals, today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved Winlevi® (clascoterone) cream 1% for the treatment of acne vulgaris in patients aged twelve years and older. This approval marks another important milestone in Cosmo’s global dermatology expansion and r
Healthcare and Hospitals, Health
2025-10-07 1:09 AM EDT | Cosmo Pharmaceuticals N.V.